ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Expression, Prognostic and Functional Analysis of SRSF Family Proteins in Non-small Cell Lung Cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide, and its occurrence and development are closely related to complex molecular mechanisms. Alternative splicing of precursor mRNA is a key step in gene expression regulation, and its dysregulation is common in tumors. The serine/arginine-rich splicing factor (SRSF) family, a core protein family in splicing regulation, has been confirmed to play oncogenic roles in various cancers. However, systematic research on the SRSF family in NSCLC remains insufficient. This study aims to systematically analyze the specific expression patterns, clinical prognostic value, collaborative mechanisms and potential biological functions of SRSF individual members in NSCLC by the combination of bioinformatics analysis and experimental verification.
methodsThis study integrated NSCLC transcriptome data and clinical information from public databases such as The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE), and systematically analyzed the differential expressions of SRSF family members. Kaplan-Meier survival analysis was performed to assess the correlation between the expression levels of each SRSF member and patients' overall survival (OS). Furthermore, co-expression network analysis and Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were employed to explore the biological processes and signaling pathways potentially involved by the SRSF family. Moreover, the expression and function of key members were verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR), cell counting kit-8 (CCK-8) and cell proliferation experiments in clinical samples and cell lines.
resultsMultiple members of the SRSF family (e.g., SRSF1, SRSF2, SRSF3, SRSF6, SRSF7, SRSF9, SRSF10) were found to be significantly upregulated in NSCLC tissues and cell lines. Survival analysis indicated that high expression of SRSF9 was associated with poor prognosis, while low expressions of SRSF11 and SRSF12 also indicated unfavorable outcomes. Functional enrichment analysis revealed that the SRSF family is not only involved in RNA splicing but also significantly enriched in pathways related to protein homeostasis, cellular stress response, and neurodegenerative diseases. In vitro experiments confirmed that knockdown of SRSF1, SRSF2, SRSF6, SRSF9 and SRSF10 significantly inhibited the proliferation of NSCLC cells.
conclusionsThis study systematically delineates the expression and functional landscape of the SRSF family in NSCLC, confirming their potential as prognostic biomarkers and therapeutic targets. The findings suggest that the SRSF family may drive NSCLC progression by disrupting cellular homeostasis, a crucial aspect of tumorigenesis, such as protein homeostasis and stress responses. This research provides a theoretical foundation for a deeper understanding of the role of splicing dysregulation in lung cancer and for the development of novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.